Nov 15, 2021 | Clinical case

Compare your opinion with peers and Dr. Joost Boormans

Cystoscopy* has a high sensitivity for detecting carcinoma in situ (CIS) in non-muscle-invasive bladder cancer (NMIBC). Therefore, it can accurately rule out this high-grade and aggressive tumour.

 

Submit your answer and read the opinion of Dr. Joost Boormans

 

Other updates

Urinary biomarkers for the surveillance of NMIBC

Can urinary biomarkers help address some of the key limitations of cystoscopy and urine cytology in the surveillance of non-muscle-invasive bladder cancer (NMIBC)? Watch this expert presentation to discover how urinary biomarkers may support a more patient-centred and...

read more